CellSource Co., Ltd. (TYO:4880)

Market Cap	7.70B -52.6%
Revenue (ttm)	3.72B -18.5%
Net Income	89.08M -89.6%
EPS	4.50 -89.8%
Shares Out	19.85M
PE Ratio	86.32
Forward PE	n/a
Dividend	5.00 (1.29%)
Ex-Dividend Date	Oct 30, 2025

Volume	110,600
Average Volume	128,300
Open	377.00
Previous Close	383.00
Day's Range	377.00 - 395.00
52-Week Range	360.00 - 798.00
Beta	-0.32
RSI	48.85
Earnings Date	Jun 12, 2026

About CellSource

CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 148
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4880

Financial Performance

In fiscal year 2025, CellSource's revenue was 3.71 billion, a decrease of -17.73% compared to the previous year's 4.51 billion. Earnings were 10.00 million, a decrease of -98.92%.